Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biophytis ( (BPTSY) ) has shared an update.
On March 11, 2026, Biophytis announced it had raised €2.015 million in gross proceeds via a capital increase without preferential subscription rights, issuing new shares, pre-funded warrants and attached warrants to a small group of institutional investors, including Alumni Capital and Hexagon Capital Fund. The structure implies substantial potential dilution, with total shares outstanding more than doubling if all pre-funded warrants and warrants are exercised.
The company is using the proceeds to repay all variable-price convertible debt held by Atlas Capital and certain straight debt owed to Hexagon Capital Fund, while securing an interest-free extension on debt from Kreos Capital until mid-2026, significantly cleaning up its balance sheet. Remaining funds will support the establishment of a Hong Kong joint venture to launch a phase 3 sarcopenia trial, preparation of a phase 2 obesity trial in Brazil, expansion of its AI longevity platform and roughly six months of operating runway, positioning Biophytis to advance key programs while shifting away from more dilutive financing instruments.
The most recent analyst rating on (BPTSY) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Biophytis stock, see the BPTSY Stock Forecast page.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing cash burn, and negative equity), reinforced by bearish technicals with the stock trading below major moving averages. Valuation is also constrained by negative earnings and no dividend support, with only a minor offset from oversold momentum readings.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis S.A., listed on Euronext Growth Paris, is a biotechnology company developing transformative therapies aimed at improving longevity, with key clinical programs in sarcopenia and obesity. The company is building partnerships across Europe, the Americas and Asia, including a planned joint venture in Hong Kong and collaborations such as its AI-driven drug discovery work with Lynx Analytics.
Average Trading Volume: 895
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.17M
See more insights into BPTSY stock on TipRanks’ Stock Analysis page.